To evaluate human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase ( HSV -TK ) ± mediated gene therapy, we tested the utility of different viral vectors on three human cell lines DU -145, LNCaP, and PC -3. Our viral vectors were carrying a fusion gene of HSV -TK and green fluorescent protein for accurate determination of the gene transfer rate and its contribution to the treatment outcome in each case. We observed that adenoviral and lentiviral vectors were efficient vehicles for all the cell lines, whereas Semliki Forest virus and Sindbis virus vectors yielded only a few percent of transgene -positive cells. Despite sufficient gene transfer rates ( 25 ± 45% ) in the ganciclovir ( GCV ) sensitivity experiment, only DU -145 cells were efficiently destroyed under clinically relevant GCV concentrations. This was shown to be due to low level of``bystander effect'' in PC -3 and LNCaP cells. Our data demonstrate that human prostate tumors can be good targets for adenovirus -or lentivirus -mediated HSV -TK / GCV gene therapy, but each tumor should be investigated for gene transfer rate and bystander effect to warrant a sufficient treatment result.
P rostate cancer is currently one of the leading causes of male cancer deaths in the Western world. The standard treatment for advanced prostate cancer is androgen withdrawal. Most of the patients experience initially good response to the therapy. Eventually, however, the disease will progress. Today, there is no effective treatment for such hormone-refractory prostate carcinoma, and therefore, prognosis after the relapse is poor. 1 Evidently, new treatment modalities for advanced prostate cancer are urgently needed. Due to increased understanding of tumor biology and development of efficient gene transfer techniques, gene therapy shows clear potential for becoming an alternative treatment form for prostate cancer.
Prostate cancer as a target for gene therapy has been studied extensively during the last few years ( for reviews, see Refs. 2, 3 ). In addition to numerous studies with cultured prostate carcinoma cell lines and xenograft animal tumor models, at least 20 clinical trials have been reviewed by FDA ( for list of trials by December 1999, see Human Gene Therapy 10, 3067 ±3123) . Various gene transfer vectors, including retroviruses, pox viruses, herpes simplex virus ( HSV ), Semliki Forest virus (SFV ), and nonviral methods have been tested for prostate cancer cells, although the vast majority of the studies have been carried out using adenoviral vector. Adenoviral vectors, especially when equipped with a prostate -specific promoter, have been shown to be efficient vehicle for prostate cancer gene transfer, both in vitro and in vivo. However, to our knowledge, there is no published report that compares the transduction efficiency of different viral vectors in prostate cancer cells.
A number of strategies can be utilized in prostate cancer gene therapy experiments: immunomodulation of tumor cells to evoke/enhance tumor-specific immune response ( e.g., cytokines); restoration of a missing tumor-suppressor activity of the tumor cells (p53, p16) ; inhibition of an overexpressed oncogene ( antisense c-Myc ) ; induction of apoptosis by inhibiting an antiapoptotic gene ( antisense Bcl -2 ) , etc. One of the most intensively studied strategies is the so-called suicide gene therapy method, where the product of a suicide gene converts a harmless prodrug into toxic form, which kills the cells. Thymidine kinase gene of herpes simplex virus type 1 ( HSV-TK ) is probably the best -known suicide gene. The enzyme product of this gene can convert nontoxic antiviral drugs, like ganciclovir ( GCV ), into toxic form that interferes with DNA replication and destroys cells during division. 4 In addition to direct effect of HSV-TK /GCV gene therapy, it has been shown that some HSV-TK ± negative tumor cells can uptake the toxic metabolite from adjacent HSV-TK ±positive cells. This phenomenon is called``bystander effect'' 5 and its enhancing effect on tumor cell destruction has been demonstrated in many studies.
The actual relationship between gene transfer efficiency and treatment results has been difficult to determine in HSV-TK /GCV gene therapy experiments, as well as in other types of approaches. To solve this problem and study reliably the correlation between gene transfer rate of different viral vectors and the treatment result with GCV in various tumor cell types, we have constructed HSV-TK green fluorescent protein ( GFP ) fusion gene. 6 After improvement of the GFP domain for better performance in FACS analysis, 7 the fusion construct was cloned into different viral vectors and the utility of these TK -GFP viruses was demonstrated. 8 Several groups have reported preclinical gene therapy studies for prostate cancer using the HSV-TK /GCV approach 9 ± 14 and some of these investigations have already proceeded to phase I trial level and the first reports have recently been published. 15 ± 17 However, it is still unclear how suitable targets different human prostate carcinomas are for HSV-TK /GCV suicide approach in general; what is the level of gene transfer required in these cells to provide sufficient therapeutic effect; and what vector types are the best for these cells. We wanted to evaluate the feasibility of HSV-TK / GCV approach to gene therapy of prostate cancer by using three widely used human prostate carcinoma cell lines and four different viral vectors carrying the TK -GFP fusion gene. We were seeking answers to the following questions: ( a) What is the most efficient viral vector type for human prostate carcinoma cell lines? ( b) What is the role of gene transfer rate (obtained with the best vector types ) for the treatment result? ( c) What is the level of bystander effect in each cell line and how does it contribute to the treatment result?
MATERIALS AND METHODS

Plasmid constructs and viral vectors
Construction of the TK -GFP fusion construct has been described by Loimas et al. 6 Preparation of the improved TK -GFP construct ( TGL ) and its cloning into alphaviral vectors, SFV-TGL (SFV vector ) and SinTGL (Sindbis virus vector ), have been described earlier. 7 Construction of a first -generation adenoviral vector, AdTGL, and a VSV-G pseudotyped lentiviral vector, LentiTGL, has been described by Loimas et al. 8 Expression of the TK -GFP transgene is driven by human elongation factor alpha promoter in AdTGL and by cytomegalovirus promoter (CMV ) in LentiTGL, whereas in SFV-TGL and SinTGL, the expression is driven by viral subgenomic (26S) promoters. Vector propagation yielded virus preparations with following titers: AdenoTGL 1Â10 9 pfu /mL (in 293 cells ), LentiTGL 2Â10 
Cell lines
DU -145 cells ( ATCC HTB 81 ) and the cell lines for viral vector titration, 293 (ATCC CRL -1573 ), 293T ( a gift from Dr. Garry Nolan, Stanford University ), and BHK -21 ( ATCC CCL -10 ), were grown in high -glucose Dulbecco's modified Eagle's medium, PC -3 ( ATCC CRL 1435) , and LNCaP ( ATCC CRL 1740) cells were grown in RPMI 1640 medium. These media were supplemented with 10% fetal calf serum, 2 mM glutamine, 2 mM sodium pyruvate, and 50 g /mL gentamicin, and the cells were grown at 378C in the presence of 5% CO 2 . Adenoviral and lentiviral vectors. The cells were split into six -well plates (200,000/well), incubated for 20 hours, washed once with PBS, and incubated with viruses for 1 hour. After 3 days of incubation, the cells were split to 96-well plates ( 2500/ well ) , incubated for 20 hours, and exposed to GCV. Flow cytometry was performed to determine the proportion of GFP -positive cells, i.e., the transduction efficiency with each MOI used. After 5 days of incubation with GCV, MTT assay was carried out.
Transduction of cultured cells
Bystander effect experiments
For bystander studies, the cells were transduced with a high MOI of AdenoTGL as described above and flow cytometry was performed 3 days post -transduction. Based on the FACS results, the proportion of TK -GFP ± positive cells in each transduced culture was set to 10%. The cells were divided to 96 -well plates, using densities of 500± 32,000 cells / well (to obtain cultures with increasing number of cell ±cell contacts) . After incubation with 5 g /mL GCV for 5 days, cell viability was measured by MTT assay. The bystander effect was demonstrated by a higher degree of cytotoxicity than the Cancer Gene Therapy, Vol 8, No 2, 2001 10% that was based on the presence of positive cells in the culture. The idea of this method has been presented by Samejima and Meruelo. 18 
Statistical analysis
Results from GCV sensitivity and bystander effect experiments were analyzed with two -tailed t test. Differences were considered significant when the probability ( P ) was < .05.
RESULTS
Transduction of prostate carcinoma cell lines with different viral vectors
The efficiency of different viral vector types was studied by transducing the human prostate carcinoma cell lines ( PC -3, DU -145, and LNCaP) with adenoviral -, lentiviral -, SFV-, and Sindbis viral vectors carrying the TK -GFP fusion construct. Two different MOIs, 0.3 and 3, were used to obtain results that resemble an in vivo situation, where gene transfer efficiency usually remains modest. Transduction efficiency and level of transgene expression in each cell line were examined using flow cytometry 1 to 4 days post -transduction ( Fig 1 ) . Adenoviral vector had the best efficiency, yielding gene transfer rates from 23% to 53%. Lentiviral vector was almost as good a vector for the studied cells as adenovirus, yielding 29± 39% positive cells. Both alphaviral vectors were inefficient for all the cell lines (SFV 0.6 ±3.7%, Sindbis 0.1± 3.6% positive cells) . SFV vector turned out to be slightly better than Sindbis vector, yet its performance was poor compared to adenoviral and lentiviral vectors. Despite presence of RCVs in the SindbisTGL preparation, no progressive spreading of the virus was observed in any of the cell lines.
Flow cytometry provided information about the level of transgene expression with different viral vectors. Alphaviral vectors, SFV and Sindbis, gave poor transduction efficiency, but the few positive cells displayed high TK -GFP expression. For example, in DU -145 cell line, SFV and Sindbis vectors ( MOI 3 ) yielded TK -GFP expression levels 83 and 39 times higher, respectively, than the background fluorescence of the nontransduced population. Adenoviral and lentiviral vectors ( MOI 3) yielded lower mean expression levels (27 and 19 times higher than the background, respectively ), but these values were shown to be sufficient for sensitizing the cells to GCV (see GCV sensitivity of prostate carcinoma cells transduced with TK -GFP vectors). During the course of this study, transduction experiments were repeated several times. It turned out that the actual transduction efficiency varied from experiment to experiment with all the cell lines. Although the experiments were carried out by the same person, the same vector batch was used, and a standard operation protocol was followed, there was some variation in the gene transfer rate. For example, five independent transduction experiments using LNCaP cells yielded mean efficiency ( from triplicate transductions ) ranging from 35% to 57% with adenovirus and 7% to 17% with lentivirus (Table 1 ). These data emphasize the utility of coupled therapeutic gene ± marker gene vectors and offer a cautionary example about the fact that the actual transduction efficiency is always dependent on the ambient conditions, not only on the amount of viral vector used.
GCV sensitivity of prostate carcinoma cells transduced with TK -GFP vectors
As the alphaviral vectors, SFV-TGL and SinTGL, turned out to be inefficient for human prostate carcinoma cell lines, the subsequent tests were carried out with AdenoTGL and LentiTGL vectors. The purpose of these experiments was to study the relationship between gene transfer efficiency and treatment result with two different viral vectors. The cell lines were transduced with AdenoTGL (MOIs 3 and 0.3) and LentiTGL ( MOI 0.3) and incubated for 4 days. After transduction rate determination by FACS, the cells were incubated in the presence of increasing concentrations of GCV for 5 days, followed by viability analysis using MTT assay. Our criterion for a good treatment efficacy was 60 ± 80% cell destruction under 5 g/ mL GCV (comparable to the standard human dose of 5 mg /kg /d ).
The results illustrated in Figure 2 revealed that high transduction rate is essential prerequisite for effective cell killing. As demonstrated with DU -145 cells, 4.5% gene transfer rate with low MOI of AdenoTGL killed only about 25% of the cells ( under 5 g/mL GCV ), whereas LentiTGL ( rate 9.1% ) already caused more prominent cell destruction and higher MOI of AdenoTGL ( rate 45% ) very efficiently killed the cells, even when the GCV concentration was as low as 0.1 g /mL. Part of this effect in these cells can also be due to cytotoxicity of the vector alone. Namely, the viability of DU -145 cells decreased with the higher MOI of AdenoTGL even without GCV treatment, yet the difference was not statistically significant (Fig 2, upper panel ) . We also obtained more prominent cytotoxicity when higher MOIs of AdenoTGL were used. MOI of 10 yielded 74% of TK -GFP ±positive DU -145 cells and reduced the viability of the cells by 60% ( results not shown ).
LNCaP cells were transduced quite well with both AdenoTGL (rate 35% ) and LentiTGL ( rate 11% ), but this caused only about 50% cell destruction at 5 g /mL GCV. PC -3 cells were the poorest targets for both of the viral vectors used, yet the best transduction rate with AdenoTGL was almost 25%. Nevertheless, this was not sufficient for a good treatment result and the outcome was similar to the results with LNCaP cells, yielding only 50% of dead cells under 5 g /mL GCV. The viability difference between nontransduced cells and transduced PC -3 cells was not statistically significant.
Bystander effect in human prostate carcinoma cell lines
As demonstrated in GCV sensitivity of prostate carcinoma cells transduced with TK -GFP vectors, high transduction efficiency was necessary, but not sufficient per se to provide good treatment result. One of the factors affecting the efficacy of TK -GCV suicide gene therapy approach is the bystander effect, i.e., how well the neighboring cells are capable of sharing the toxic derivatives of GCV. In this study, we determined the presence of this effect by setting the proportion of TK -GFP ± positive cells to 10% and splitting the cells in different densities on 96 -well plates. This way, we obtained cultures where the degree of cell ±cell contacts varied. The bystander effect was demonstrated by a higher than 10% cell destruction in the wells, where cells were forming physical contacts with their neighbors.
The results of this experiment ( Fig. 4 ) confirmed the contribution of the bystander effect to the treatment outcome. The only cell line that showed >10% cell death under GCV with more than 4000 cells /well (the approximate threshold density for appearance of cell ± cell contacts ) was DU -145. This is in accordance with the results from GCV sensitivity experiments, where all the DU -145 cells were killed with GCV, although only <50% of the cells was TK -GFP ± positive. LNCaP cells displayed low level of bystander effect compared to DU -145 cells and the difference between the GCV-treated and untreated cells was not statistically significant. PC -3 cells did not show any sign of bystander effect and 10% proportion of positive cells did not cause statistically significant GCV sensitivity. Thus, the lack of strong bystander effect in PC -3 and LNCaP cells can explain the poor treatment efficacy in the previous experiment.
DISCUSSION
Prostate cancer is one of the human malignancies that have been investigated as a target for gene therapy. One of the most frequently used approaches has been HSV-TK gene transfer, followed by GCV treatment. This approach has been successfully used in many preclinical investigations and recently, some data from clinical trials have been published ( for references, see the introduction ). The purpose of this study was to determine whether human prostate cancer is a good target for viral vector ± mediated HSV-TK suicide gene therapy. We used four different viral vector types (adeno -, lenti-, SFV-, and Sindbis virus ) carrying the HSV-TK -GFP fusion gene to transduce three human prostate carcinoma cell lines ( PC -3, LNCaP, and DU -145) . These are the most commonly used cell lines in the studies on prostate cancer. They all originate from metastatic lesions of prostate. The growth of PC -3 and DU145 is androgen-independent, whereas LNCaP is androgen -sensitive. Thus, they represent different forms of the advanced prostate cancer. 19 ± 21 The goal of this study was to find out how well different viral vectors perform on these cells, how much gene transfer is needed for sufficient The first part of the study tried to determine how well different viral vectors can transduce these cell lines. Even though we feel that side -by -side comparison of different viral vector types can provide valuable information about their utility in prostate cancer gene therapy research, it should be pointed out that the titers of different vector types were evaluated using different target cells and transduction protocols. Hence, the MOIs used are not absolute values and transduction efficiencies cannot be compared directly. Instead of accurate values, these results should be used as guidelines on whether a viral vector is potentially useful for the tested target cell type or not.
We chose to use low MOIs ( 0.3 or 3 ) to avoid too optimistic results. Namely, in in vivo situation, high MOIs probably occur only locally ( at injection site ) and most of the cells in a transduced tumor mass will meet only a few virus particles. Our results (Fig 1) demonstrate that low MOIs of adenoviral and lentiviral vectors yield superior transduction rate compared to alphaviral vectors, SFV and Sindbis. This is in accordance with our previous findings 7, 8 showing that some human cells can be resistant to low amounts of alphaviral vectors. Hardy et al 22 have reported that human prostate cancer cell lines can be transduced with SFV vector and transduction with SFV-GFP causes cell death in PPC -1 cell line at high MOI (5 ± 50) . The PPC -1 cell line is actually known to be same as PC -3 cell line. 23 Thus, not surprisingly low virus amounts yielded similar transduction rate as in this report.
Even though adenoviral vectors have been used extensively in prostate cancer gene therapy research and it is a vector of choice in some gene therapy trials, 15 ± 17 the in vitro efficiency of this vector type for human prostate carcinoma cells has not been studied systematically. Eastham et al 9 showed that PC -3 and DU -145 cells can be killed with GCV after transduction with high MOIs of Ad RSV-tk. In their study, DU -145 cells were killed with much lower MOI than PC -3 cells, but the reason for this difference was not determined. The poorer permissiveness of PC -3 cells to adenoviral vectors was also shown in another study, 24 where only 5% of these cells stained lacZ -positive after transduction with MOI 100 of AdRSVlacZ. A study by Kim et al 25 demonstrated much higher efficiencies with AdCMVlacZ MOI 100. In their report, gene transfer rates close to 100% were detected in DU -145, PC -3, and LNCaP cells. However, they also used AdCMVLuc with the same MOI and observed that the gene transfer rate (based on luciferase activity ) in PC -3 cells was 5 ±10 times lower than that in DU -145 and LNCaP cells. Nevertheless, our own results confirm that adenoviral vector is an efficient gene transfer vehicle for most human prostate cancer cells and reasonable transduction rates can be obtained even with low amounts of virus.
Lentiviral vectors have been tested for various types of target cells or tissues and the results have been very encouraging (for review, see Ref. 26 ). Because VSV-G pseudotyped lentiviruses can efficiently introduce new genetic material to a variety of nondividing cells, they are potential vectors for many solid tumors. We have earlier investigated other types of tumor cell lines and concluded that lentiviral vectors are efficient for both glioma and renal carcinoma cells. 8 The present study confirms the utility of lentiviral vectors in gene transfer to tumor cells in vitro and suggests that lentiviral vectors could compete even with adenoviral vectors, especially in case of cell types resembling PC -3 cell line.
Our transduction efficiency experiments with TK -GFP ± carrying viral vectors also yielded a demonstration of the utility of marker gene ± therapeutic gene fusion constructs. The cautionary example shown in Table 1 emphasizes that even though a viral vector preparation has been titrated and its efficiency in a target cell /tissue has been determined, exactly the same transduction protocol does not yield the same transduction rate every time. However, if the actual transduction efficiency can be determined in each case ( by using a fusion of marker gene and therapeutic gene ), the variation is not that hazardous to interpretation of results.
After verifying that adenoviral and lentiviral vectors were the most efficient gene transfer vehicles for the studied human prostate carcinoma cell lines, we examined what the correlation between actual transduction rate and cell destruction efficiency by GCV is. Results shown in Figure  2 suggest that only DU -145 cells are good targets for HSV-TK /GCV ± mediated cancer gene therapy. About 10% gene transfer rate ( obtained with LentiTGL ) was sufficient to sensitize the cells to GCV and 45% rate ( AdenoTGL ) caused almost complete cell destruction with 0.1 g/mL GCV. It is likely that cytotoxicity of the vector alone contributed to this result, too, because transduced cells had poorer viability even without GCV treatment (Fig 2, upper  panel) . The vector effect in DU -145 cells can be a combination of a good transduction efficiency (several vector particles can enter the same cell) and rapid proliferation ( can allow adenoviral vector replication 27 ) of these cells.
PC -3 and LNCaP cells were transduced up to 24% and 35%, respectively, with AdenoTGL, but this was not enough for satisfactory treatment result. Both cell lines became more sensitive to GCV, but the fraction of viable cells after 5 days in 5 g/ mL GCV was still 50% or higher. It is likely that this type of prostate cancer cells requires close to 100% gene transfer rate to be efficiently killed by GCV. This situation is difficult to reach in vivo with current gene transfer vectors and our data suggest that some prostate tumors cannot be treated successfully with this suicide gene therapy method.
To find reasons for poor treatment result of PC -3 and LNCaP cells, we studied the bystander effect present in all three cell lines. As illustrated in Figure 3 , only DU -145 cells have a significant bystander effect, i.e., > 10% of GCVtreated cells die when the cells form physical contacts with other cells. These results are in accordance and can explain the data presented earlier by Eastham et al. 9 They reported that DU -145 cells can be killed more efficiently than PC -3 cells with 10 g /mL GCV after transduction to low MOIs of TK -carrying adenoviral vectors. Our data suggest that this is due to both lower transduction rate and missing bystander effect in PC -3 cells. Lockett et al 24 also reported``not extensive'' bystander effect in PC -3 cells and proposed that it was the reason for poor treatment result with the HSV-TK / GCV gene therapy method.
It is suggested that the bystander effect is mediated through cell ± cell gap junctions formed of proteins called connexins. These channels can act as pathways for phosphorylated forms of GCV to travel from one cell to its neighbors. The expression of connexins in prostate cancer cells has been investigated recently because it has been proposed that lack of gap junctions is one of the hallmarks of more malignant types of cancer cells. 28 ± 31 These reports present somewhat conflicting data about the connexin status/level of intercellular communication of the cell lines studied in our paper. Mehta et al 29 show that PC -3 is the only cell line that expresses connexin 43 and displays cell ± cell communication, whereas Hossain et al 30 claim that in PC -3 and LNCaP cells, the connexin 43 expression is virtually undetectable. Even though the latter report would better explain our results, it remains difficult to judge as to what is the real connexin status of these cell lines and whether these molecules play any role in the level of the bystander effect of the prostate carcinoma cells.
CONCLUSION
The data presented in this paper confirm that adenoviral vectors are suitable for gene transfer to most prostate carcinoma cells, but lentiviral vectors can offer an alternative vehicle for slowly proliferating tumor cells. The true utility of these vector types is currently being evaluated in different animal tumor models. Our data also suggest that one should be cautious before continuing the attempts to treat prostate tumors with the HSV-TK /GCV approach and determine whether the transduction rate with the vector of choice and the degree of bystander effect in the target tumor are adequate to give sufficient treatment result. 
